An open-label, two-part, single sequence study to examine the effects of lapatinib on the pharmacokinetics of orally administered digoxin in subjects with metastatic ErbB2 [erythroblastic leukemia viral oncogene homolog 2] positive breast cancer.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Lapatinib (Primary) ; Digoxin
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Jul 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.